
Oligonucleotide to inhibit HMGB1


~ Inhibition of Inflammatory Diseases using ISM ODN ~

KEY INVENTION

A novel oligonucleotide (ISM ODN) to strongly bind to HMGB1 (High Mobility Group Box 1) has been developed to inhibit inflammatory diseases.



SUMMARY of INVENTION



cf. LPS: Lipopolysuccaride (Septic shock by high dose), ARDS : Acute Respiratory Distress Syndrome, ConA: Concanavalin A (Fulminant hepatitis by high dose)

APPLICATION expected

- © Development of the therapeutic methods for inflammatory or autoimmune diseases by targeting HMGB1
- © Development of the methods to analyze the roles or functions of HMGB1 as inflammatory cytokines
- © Elucidation of the biodefense mechanism of HMGB1 in cytoplasm, including the relevance to autophagy

	Tadatsugu Taniguchi (University of Tokyo, Honorary Professor) Hideyuki Yanai (The University of Tokyo, Associate Professor)	
Licensable Patent		
Title of Invention:	Inhibitor of HMGB protein-mediated immune response activation	
International Publication	n No.: WO2012036215	
Contact:	IP Management & Licensing Group,	
	Department of Intellectual Property Management, JST	
	TEL) +81-3-5214-8486 email) <u>license@jst.go.jp</u>	
	URL) www.jst.go.jp/chizai/	